US Medical Journal: Sinopharm Effective Against Coronavirus
The Journal of the American Medical Association (JAMA) shared the entire documentation of the Sinopharm vaccine, developed by China National Biotec Group Company (CNBG). The study, overwhelmingly made up of younger, healthy male volunteers, concluded that the vaccine is 72.8 and 78.1 percent effective against the coronavirus.
The long-awaited phase three clinical trials of the Sinopharm vaccine have finally been shared, showing that it is effective. The large scale study involved 40,832 volunteers from the United Arab Emirates, Bahrain, Egypt, and Jordan.
Very Few Elders in Sinopharm Vaccine Clinical Trials
Participants were either given two doses within three weeks or a placebo. Two weeks before their second inoculation, significantly more non-vaccinated people had caught the virus than those who were vaccinated at least once.